William Blair Predicts argenex's Q3 Earnings (NASDAQ:ARGX)

Key Points

• William Blair has raised its Q3 2025 earnings per share estimate for argenex to $4.60, slightly up from the previous estimate of $4.57.
• In its last earnings report, argenex reported earnings per share of $3.74, surpassing analyst expectations of $2.84, with a revenue of $866.79 million against estimates of $776.82 million.
• Several analysts have increased their target prices for argenex, with recommendations indicating a strong buying interest, giving it a consensus rating of "Buy" and an average price target of $813.32.

argenex SE (NASDAQ:ARGX - Free Report) - William Blair raised their Q3 2025 earnings per share estimates for argenex in a note issued to investors on Friday, October 10th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of $4.60 for the quarter, up from their prior estimate of $4.57. The consensus estimate for argenex's current full-year earnings is $3.13 per share.

argenex (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating analysts' consensus estimates of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The firm had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million.

Several other equities analysts have also recently issued reports on ARGX. Truist Financial upped their target price on shares of argenex from $700.00 to $918.00 and gave the company a "buy" rating in a research note on Monday, September 15th. Wells Fargo & Company increased their price objective on shares of argenex from $741.00 to $756.00 and gave the company an "overweight" rating in a research report on Thursday, July 31st. Stifel Nicolaus set a $882.00 price target on argenex in a report on Thursday, September 18th. Bank of America increased their price target on argenex from $880.00 to $887.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Finally, Guggenheim reissued a "buy" rating and issued a $1,070.00 target price on shares of argenex in a report on Thursday, September 18th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $813.32.

argenex Trading Down 1.0%

argenex stock opened at $796.92 on Monday. The business's fifty day simple moving average is $719.96 and its two-hundred day simple moving average is $628.00. argenex has a 12 month low of $510.05 and a 12 month high of $808.43. The company has a market capitalization of $48.77 billion, a price-to-earnings ratio of 40.87, a price-to-earnings-growth ratio of 0.86 and a beta of 0.46.

Institutional Trading of argenex

A number of large investors have recently made changes to their positions in ARGX. Millennium Management LLC grew its holdings in argenex by 316.9% during the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company's stock valued at $158,977,000 after purchasing an additional 204,180 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of argenex by 114.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company's stock valued at $163,775,000 after buying an additional 158,476 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of argenex by 103.9% during the second quarter. Franklin Resources Inc. now owns 279,803 shares of the company's stock valued at $154,233,000 after buying an additional 142,606 shares during the last quarter. BNP Paribas Financial Markets grew its position in argenex by 1,203.4% in the 1st quarter. BNP Paribas Financial Markets now owns 133,359 shares of the company's stock valued at $78,931,000 after acquiring an additional 123,127 shares during the last quarter. Finally, Braidwell LP grew its position in argenex by 99.2% in the 1st quarter. Braidwell LP now owns 160,849 shares of the company's stock valued at $95,201,000 after acquiring an additional 80,083 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.